Drugs Xagena
Bisphosphonates are drugs commonly used to prevent and treat osteoporosis in post-menopausal women. They are widely used in the management of advanced cancers that have metastasized to the bone, w ...
Novartis has a comprehensive portfolio of cardiovascular products both in the market ( Diovan and Lotrel ) as well as in development ( such as LAF237 and SPP100 ), for the treatment of hypertension, d ...
Researches at Elkhart General Hospital, in United States, have assessed the prevalence of osteonecrosis of the jaw in patients receiving bisphosphonate therapy and in those who were bisphosphonate naï ...
Aclasta ( Zoledronic acid 5 mg ) has received European Union approval as the first once-yearly treatment for women with postmenopausal osteoporosis. Unlike oral bisphosphonate therapies taken dai ...
Most of the cases of osteonecrosis of the jaw are seen in oncology patients that, besides intravenous bisphosphonates, have received chemotherapy in the long term for their base disease with or with ...
There is a well-known risk of deterioration in renal function with intravenous bisphosphonates administered at a rapid infusion rate. ADRAC ( Adverse Drug Reactions Advisory Committee ) has received ...
Zometa ( Zoledronic acid ) is indicated for the prevention of skeletal related events ( pathological fractures, spinal compression, radiation or surgery to bone, or tumor-induced hypercalcemia ) in pa ...
Key safety concerns with Denosumab ( Xgeva ) included in the Warnings and Precautions section of the existing product labeling involve the risks of osteonecrosis of the jaw ( ONJ ) and hypocalcemia. O ...
